Scientists have long argued that giving people one course of the COVID-19 vaccine may not be long-term, may require strengthening staff, or even annual vaccinations.
In recent days, this proposal has begun to sound less hypothetical.
Vaccine manufacturers are starting to get new shots, although they seem to be more convinced of the need for amplifiers than independent scientists have.
Pfizer CEO Albert Burlan said Thursday that a third dose of the company’s COVID-19 vaccine will “probably” be needed within a year of the initial two doses followed by annual vaccinations.
Dr David Keisler, who is leading the Biden administration’s vaccine effort, told a House subcommittee on Thursday that the government was also looking ahead. One factor in the game is the spread of coronavirus variants; can further vaccination better target mutant strains?
Burla said the “probable scenario” was “the third dose, which is in six to 12 months, from there it will be an annual vaccination.”
Moderna said this week that it was working to boost its vaccine, with Johnson & Johnson saying its one-shot vaccine would likely be given annually.
Kessler stressed the “strong effectiveness” of current vaccines, including against the alternatives, but said the government was “taking steps to develop the next generation of vaccines that will work against those options if they are actually more effective.”
He was one of a number of high-ranking federal health officials at the House of Representatives who begged Americans to get vaccinated, trying to reassure people that all federally approved vaccines are safe. They said little about the John Onson John John Onson resumption of staff, which was stopped by the Food and Drug Administration to investigate a rare blood clotting disorder.
Late Thursday, the Centers for Disease Control and Prevention announced that it had scheduled a new emergency hearing on April 23.
As of Thursday, more than 125 million people in the country had received at least one dose of the COVID-19 vaccine, including about 78 million who had been fully vaccinated with the single-dose, single-dose, single-dose vaccine. Pfizer-BioNTech և Modern:
In February, Pfizer and its partner BioNTech announced plans to test a third shot of upgrading their initial vaccine. The FDA says vaccine developers do not need to conduct lengthy trials of vaccines that are tailored to protect against variations.
Moderna said on Tuesday that its vaccine continued to provide strong protection against COVID-19 in the United States six months after it was introduced, company chief executive Stephen Bankel told CNBC, adding that he hoped to develop reinforcements by the fall. :